119 related articles for article (PubMed ID: 9180162)
21. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3.
Réhault S; Monget P; Mazerbourg S; Tremblay R; Gutman N; Gauthier F; Moreau T
Eur J Biochem; 2001 May; 268(10):2960-8. PubMed ID: 11358513
[TBL] [Abstract][Full Text] [Related]
22. The structure basis of the poor fibrin specificity of urokinase (II)--The inhibition of urokinase A chain 149-157 on the fibrin stimulated activation of plasminogen by tissue type plasminogen activator.
Song A; Liu JN; Yu RR; Cui DF; Zhou TM; Cui HR; Zhu DX
Sci China B; 1992 Aug; 35(8):966-73. PubMed ID: 1338753
[TBL] [Abstract][Full Text] [Related]
23. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin.
Ichinose A; Fujikawa K; Suyama T
J Biol Chem; 1986 Mar; 261(8):3486-9. PubMed ID: 3081506
[TBL] [Abstract][Full Text] [Related]
24. The steady states and dynamics of urokinase-mediated plasmin activation.
Venkatraman L; Yu H; Bhowmick SS; Dewey F; Tucker-Kellogg L
Pac Symp Biocomput; 2010; ():190-200. PubMed ID: 19908371
[TBL] [Abstract][Full Text] [Related]
25. Human single-chain urokinase is activated by the omptins PgtE of Salmonella enterica and Pla of Yersinia pestis despite mutations of active site residues.
Järvinen HM; Laakkonen L; Haiko J; Johansson T; Juuti K; Suomalainen M; Buchrieser C; Kalkkinen N; Korhonen TK
Mol Microbiol; 2013 Aug; 89(3):507-17. PubMed ID: 23763588
[TBL] [Abstract][Full Text] [Related]
26. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.
Lin Y; Harris RB; Yan W; McCrae KR; Zhang H; Colman RW
Blood; 1997 Jul; 90(2):690-7. PubMed ID: 9226169
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen.
Miles LA; Greengard JS; Griffin JH
Thromb Res; 1983 Feb; 29(4):407-17. PubMed ID: 6344314
[TBL] [Abstract][Full Text] [Related]
28. Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2.
Bourgeois L; Brillard-Bourdet M; Deperthes D; Juliano MA; Juliano L; Tremblay RR; Dubé JY; Gauthier F
J Biol Chem; 1997 Nov; 272(47):29590-5. PubMed ID: 9368023
[TBL] [Abstract][Full Text] [Related]
29. Regulation of single chain urokinase by small peptides.
Higazi A al-R ; Cines D
Thromb Res; 1996 Nov; 84(4):243-52. PubMed ID: 8948049
[TBL] [Abstract][Full Text] [Related]
30. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk.
Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP
Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2.
Mize GJ; Wang W; Takayama TK
Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807
[TBL] [Abstract][Full Text] [Related]
32. Soluble human urokinase receptor is composed of two active units.
Higazi AA; Mazar A; Wang J; Quan N; Griffin R; Reilly R; Henkin J; Cines DB
J Biol Chem; 1997 Feb; 272(8):5348-53. PubMed ID: 9030610
[TBL] [Abstract][Full Text] [Related]
33. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation.
Deperthes D; Frenette G; Brillard-Bourdet M; Bourgeois L; Gauthier F; Tremblay RR; Dubé JY
J Androl; 1996; 17(6):659-65. PubMed ID: 9016396
[TBL] [Abstract][Full Text] [Related]
34. Covalent molecular weight approximately 92 000 hybrid plasminogen activator derived from human plasmin amino-terminal and urokinase carboxyl-terminal domains.
Robbins KC; Tanaka Y
Biochemistry; 1986 Jun; 25(12):3603-11. PubMed ID: 2941075
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the activation of pro-urokinase by thermolysin.
Marcotte PA; Henkin J
Biochim Biophys Acta; 1993 Jan; 1161(1):105-12. PubMed ID: 8422417
[TBL] [Abstract][Full Text] [Related]
36. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein.
Slawin KM; Shariat SF; Nguyen C; Leventis AK; Song W; Kattan MW; Young CY; Tindall DJ; Wheeler TM
Cancer Res; 2000 Dec; 60(24):7142-8. PubMed ID: 11156423
[TBL] [Abstract][Full Text] [Related]
37. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.
Lövgren J; Rajakoski K; Karp M; Lundwall â ; Lilja H
Biochem Biophys Res Commun; 1997 Sep; 238(2):549-55. PubMed ID: 9299549
[TBL] [Abstract][Full Text] [Related]
38. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors.
Lövgren J; Airas K; Lilja H
Eur J Biochem; 1999 Jun; 262(3):781-9. PubMed ID: 10411640
[TBL] [Abstract][Full Text] [Related]
39. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Schmitt M; Goretzki L; Jänicke F; Calvete J; Eulitz M; Kobayashi H; Chucholowski N; Graeff H
Biomed Biochim Acta; 1991; 50(4-6):731-41. PubMed ID: 1801751
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue.
Mikolajczyk SD; Millar LS; Marker KM; Rittenhouse HG; Wolfert RL; Marks LS; Charlesworth MC; Tindall DJ
Cancer Res; 1999 Aug; 59(16):3927-30. PubMed ID: 10463585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
